Carvedilol nanoparticles were intended to be manufactured and evaluated using various hydrophilic polymers. Carvedilol was selected as an effective pharmaceutical agent for gastro-retentive nanoparticles due to its absorptive nature in the upper gastrointestinal tract and stomach, frequent dosing requirements, and limited bioavailability. In order to produce nanoparticles that are non-toxic to the body, the nanoprecipitation method was utilized to eliminate the need for surfactants or chlorinated solvents. The carvedilol nanoparticulate formulations prepared with various polymers in a 1:1 ratio exhibited particle sizes ranging from 214.09 to 744.09 nm, a polydispersity index (PDI) ranging from 0.82 to 1.1, zeta potential values ranging from -15.2 to +35.6 mV, loading efficiency ranging from 9.47% to 18.45%, and entrapment efficiency ranging from 54.17% to 76.4%. The nanoparticulate formulation prepared using gelatin in a 1:1 ratio yielded good results. The average particle size was 744.09 nm, the polydispersity index (PDI) was 0.82, the zeta potential was 15.2 mV, the loading efficiency was 9.47%, and the entrapment efficiency was 74.44%.